# OnCo record urothelial (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/urothelial/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "urothelial" ;
  schema:name "Bladder & urothelial cancer"@en ;
  schema:alternateName "BLCA"@en, "TCGA-BLCA"@en, "bladder urothelial carcinoma (TCGA BLCA cohort)"@en, "Transitional Cell Cancer of the Renal Pelvis and Ureter"@en ;
  schema:description "Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."@en ;
  schema:url <https://onco.cc/cancers/urothelial/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Bladder_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q504775> ;
  schema:citation <https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder> ;
  onco:tag "gu" ;
  onco:related <https://onco.cc/cancers/urethral/>, <https://onco.cc/collections/src-urotoday/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/bcg-and-intravesical-therapy/>, <https://onco.cc/technologies/cystoscopy-turbt/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/cytokine-therapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/peptide-drug-conjugate/> ;
  onco:targets <https://onco.cc/targets/nectin4/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/trop2/> ;
  onco:drugs <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/ventana-pd-l1-sp142/>, <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/drugs/valrubicin/>, <https://onco.cc/drugs/vinflunine/> ;
  onco:companies <https://onco.cc/companies/mabwell-shanghai-bioscience/>, <https://onco.cc/companies/molecular-partners/>, <https://onco.cc/companies/suzhou-forlong-biotechnology/>, <https://onco.cc/companies/astellas/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/cg-oncology/>, <https://onco.cc/companies/immunitybio/>, <https://onco.cc/companies/ferring/>, <https://onco.cc/companies/bicycle-therapeutics/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/mount-sinai/>, <https://onco.cc/institutions/the-christie/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/bladder-cancer-signalling/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/nmibc-vs-mibc/>, <https://onco.cc/terms/bcg-unresponsive/>, <https://onco.cc/terms/fgfr3/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/ev-302/>, <https://onco.cc/trials/ev-303/>, <https://onco.cc/trials/ev-304/>, <https://onco.cc/trials/nct04658862/>, <https://onco.cc/trials/hr-nmibc/>, <https://onco.cc/trials/nct07424287/>, <https://onco.cc/trials/nct07726992/>, <https://onco.cc/trials/nct05754853/>, <https://onco.cc/trials/nct07480356/>, <https://onco.cc/trials/nct06331299/>, <https://onco.cc/trials/nct06919965/>, <https://onco.cc/trials/nct04165317/>, <https://onco.cc/trials/companion-002/>, <https://onco.cc/trials/nct07218380/>, <https://onco.cc/trials/nct06774131/>, <https://onco.cc/trials/nct05243550/>, <https://onco.cc/trials/nct07815665/>, <https://onco.cc/trials/nct05302284/>, <https://onco.cc/trials/nct07720284/>, <https://onco.cc/trials/nct05037279/>, <https://onco.cc/trials/nct07419295/>, <https://onco.cc/trials/nct07129993/>, <https://onco.cc/trials/nct03682068/>, <https://onco.cc/trials/nct06111235/>, <https://onco.cc/trials/nct06857175/>, <https://onco.cc/trials/nct06319820/>, <https://onco.cc/trials/nct06211764/>, <https://onco.cc/trials/nct07566156/>, <https://onco.cc/trials/nct03036098/>, <https://onco.cc/trials/nct05704244/>, <https://onco.cc/trials/nct02516241/>, <https://onco.cc/trials/nct06510374/>, <https://onco.cc/trials/nct05943106/>, <https://onco.cc/trials/nct06960577/>, <https://onco.cc/trials/nct06545955/>, <https://onco.cc/trials/nct04241185/>, <https://onco.cc/trials/nct06592326/>, <https://onco.cc/trials/nct03967977/>, <https://onco.cc/trials/nct05911295/>, <https://onco.cc/trials/nct07393542/>, <https://onco.cc/trials/nct03711032/>, <https://onco.cc/trials/nct06879145/>, <https://onco.cc/trials/nct04960709/>, <https://onco.cc/trials/nct06493552/>, <https://onco.cc/trials/nct07106762/>, <https://onco.cc/trials/nct06196736/> ;
  onco:journals <https://onco.cc/journals/clinical-genitourinary-cancer/>, <https://onco.cc/journals/urologic-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/ak146d1/>, <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/shr-8068/>, <https://onco.cc/drugs/shr-a2102/>, <https://onco.cc/drugs/domvanalimab/>, <https://onco.cc/drugs/cetrelimab/>, <https://onco.cc/drugs/budigalimab/>, <https://onco.cc/drugs/livmoniplimab/>, <https://onco.cc/drugs/shr-1501/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/mrg002/>, <https://onco.cc/drugs/tara-002/>, <https://onco.cc/drugs/ugn-103/>, <https://onco.cc/drugs/tar-210/>, <https://onco.cc/drugs/sasanlimab/>, <https://onco.cc/drugs/tovecimig/>, <https://onco.cc/drugs/vepugratinib/>, <https://onco.cc/drugs/ugn-104/>, <https://onco.cc/drugs/t3011/>, <https://onco.cc/drugs/tyra-300/>, <https://onco.cc/drugs/absk061/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/trials/ev-304/>, <https://onco.cc/drugs/cretostimogene/>, <https://onco.cc/trials/bond-003/>, <https://onco.cc/drugs/tar-200/>, <https://onco.cc/ideas/idea-bladder-preservation-mibc/>, <https://onco.cc/ideas/idea-urine-ctdna-surveillance/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/zelenectide-pevedotin/>, <https://onco.cc/pairings/durvalumab-plus-bcg/>, <https://onco.cc/pairings/ev-pembro-continuum/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/cystoscopy-turbt/> ;
  onco:standardOfCare <https://onco.cc/terms/nmibc-vs-mibc/>, <https://onco.cc/terms/turbt/>, <https://onco.cc/terms/intravesical-therapy/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/cytokine-therapy/>, <https://onco.cc/terms/nmibc-vs-mibc/>, <https://onco.cc/terms/cystectomy/>, <https://onco.cc/trials/imvigor011/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/trials/ev-303/>, <https://onco.cc/trials/ev-304/>, <https://onco.cc/trials/ev-302/>, <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/cystoscopy-turbt/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/cystoscopy-turbt/>, <https://onco.cc/technologies/bcg-and-intravesical-therapy/>, <https://onco.cc/drugs/bcg-intravesical/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/trials/potomac/>, <https://onco.cc/pairings/durvalumab-plus-bcg/>, <https://onco.cc/drugs/tar-200/>, <https://onco.cc/drugs/nogapendekin-alfa/>, <https://onco.cc/drugs/nadofaragene-firadenovec/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cretostimogene/>, <https://onco.cc/trials/sunrise-1/>, <https://onco.cc/trials/bond-003/>, <https://onco.cc/trials/quilt-3-032/>, <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/ev-304/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/trials/niagara/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/pairings/ev-pembro-continuum/>, <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/ev-303/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/checkmate-274/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/trials/imvigor011/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/ev-302/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/trials/javelin-bladder-100/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/trials/thor/>, <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/ak146d1/> .